FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...

The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Tokyo, Japan and Cambridge, UK, 23 October 2024 - Nxera Pharma Co., Ltd. ("Nxera” or "the Company”; TSE 4565) - formerly ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

The global Chronic Obstructive Pulmonary Disease (COPD) treatment market is projected to experience steady growth over the ...